Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
ETH ZÜRICH has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 8 actions are distributed among 8 distinct examiners and 7 distinct art units. This distribution shows that nearly every pending matter is being handled by a different examiner in a different technical group at the USPTO.
Huma Waseem is the busiest examiner for the portfolio, currently managing 1 pending office action. With 8 distinct examiners for 8 pending actions, the workload is perfectly decentralized across the identified individuals. The busiest examiner pending count of 1 confirms that no single examiner holds a dominant position over the company's current filings.
The presence of 7 distinct art units for 8 pending office actions indicates a broad range of biotechnological and pharmaceutical research being patented. Practitioners should be prepared to manage 8 distinct examiner relationships, each potentially bringing a different perspective to the prosecution. This structure requires a coordinated approach to ensure consistency across the 7 different art units involved in the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WASEEM, HUMA | 1 | 17.7% | +20.5% |
| WOOD, BLAKE ANDREW | 1 | 71.3% | +14.4% |
| PIRO, NICHOLAS ANTHONY | 1 | 45.9% | +35.9% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| MERCADO, GABRIEL S | 1 | 42.9% | +25.7% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 183d overdue |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 9d |
| 18142195 | METHODS AND SYSTEMS FOR GENERATING AND PROVIDING USER INPUT RECOMMENDATIONS FOR RESPONDING TO A RECEIVED MESSAGE | MERCADO, GABRIEL S | 27d |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 29d |
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | — |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 183d overdue |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 9d |
| 18142195 | METHODS AND SYSTEMS FOR GENERATING AND PROVIDING USER INPUT RECOMMENDATIONS FOR RESPONDING TO A RECEIVED MESSAGE | MERCADO, GABRIEL S | 27d |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 29d |
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | — |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | — |
| 17620208 | CROSSLINKABLE HYDROGEL COMPOSITIONS | ARMSTRONG, SUSANNAH SIPPLE | — |
| Art Unit | Apps |
|---|---|
| 3686 | 1 |
| 3658 | 1 |
| 1627 | 1 |
| 2171 | 1 |
| 1671 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | 3686 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 17, 2025 |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 3658 | §102§103 | Final Rejection | 9d | Pending | Dec 22, 2023 |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | — | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 1627 | §103§112 | Final Rejection | 29d | Pending | Jun 22, 2023 |
| 18142195 | METHODS AND SYSTEMS FOR GENERATING AND PROVIDING USER INPUT RECOMMENDATIONS FOR RESPONDING TO A RECEIVED MESSAGE | MERCADO, GABRIEL S | 2171 | §103§112 | Non-Final OA | 27d | Pending | May 02, 2023 |
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 1671 | §101§112 | Non-Final OA | 183d overdue | Pending | Nov 29, 2022 |
| 17620208 | CROSSLINKABLE HYDROGEL COMPOSITIONS | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103DP | Final Rejection | — | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial